Business context and reporting period
This is Access Pharmaceuticals, Inc.’s Form 10-K for the fiscal year ended December 31, 2012—not an Abeona Therapeutics filing or a quarterly report. The company described itself as an emerging biopharmaceutical business, with marketed product MuGard, Phase 2 candidate ProLindac, and preclinical drug-delivery programs. The mismatch between the request metadata and the filing registrant should be verified.
Financial results and position
| Metric | 2012 | 2011 |
|---|---|---|
| Total revenue | $4.404 million | $1.839 million |
| MuGard U.S. net product sales | $2.865 million | $0.539 million |
| License revenue | $1.446 million | $1.181 million |
| Royalty revenue | $93,000 | $89,000 |
| Research and development expense | $2.010 million | $3.579 million |
| Total operating expenses | $8.720 million | $9.715 million |
| Loss from operations | $4.316 million | $7.876 million |
| Net loss | $10.532 million | $2.532 million |
| Net loss allocable to common stockholders | $12.531 million | $4.306 million |
| Basic and diluted loss per share | $0.52 | $0.22 |
| Net cash used in operating activities | $3.955 million | $7.609 million |
Revenue growth was primarily driven by increased MuGard sales. The company reported MuGard product costs of $267,000, versus $148,000 in 2011; gross profit on those sales was approximately $2.598 million, or about 91% of net product sales. The larger common-stockholder loss chiefly reflected a $4.770 million loss on the fair-value change in the preferred-stock derivative and $2.316 million warrant-extension expense, partly offset by derivative gains and lower operating expenses.
At December 31, 2012, cash and cash equivalents were $396,000, total current assets were $1.681 million, and current liabilities were $6.629 million. The balance sheet showed a $4.948 million working-capital deficit and total liabilities of $18.806 million. The $2.750 million secured note was reported as repaid, leaving no debt balance shown at year-end. Cash fell by $2.064 million during 2012, from $2.460 million; capital expenditures were $13,000. The filing cites a 2012 net cash burn rate of approximately $331,000 per month.
Material changes and notable items
- MuGard U.S. net sales increased to $2.865 million from $539,000. Quarterly 2012 net sales rose from $554,000 in the first quarter to $915,000 in the fourth quarter.
- In 2012, the company recognized $706,000 of previously deferred SpePharm license fees and a $500,000 termination fee after ending its European MuGard license. It was seeking a replacement European partner.
- The October 2012 Series B financing totaled $10 million: $4.703 million of new cash and approximately $5.297 million of Series A dividends converted into Series B preferred stock. The company also issued warrants for 20 million common shares at $0.50 per share. Series B carries a 12% annual dividend and senior liquidation rights.
- The company paid the $2.750 million secured note plus accrued interest and terminated the related security agreement. The filing’s debt note contains an apparent date inconsistency, stating payment occurred on November 2, 2013, while other sections report November 2, 2012.
- Research and development spending declined by $1.569 million. The company said it was prioritizing MuGard commercialization; it initiated no additional U.S. or European ProLindac trials during 2012 and terminated its Thiarabine license and trial.
- The company recorded a $291,000 write-off of Thiarabine patent costs; its patents were fully amortized or impaired by year-end. The Dallas laboratory was shut down, and most related assets were fully depreciated.
Outlook, risks and contingencies
- Management expected available capital, MuGard revenue and anticipated license receipts to fund the then-current operating level into the third quarter of 2013, but said additional financing was required within 12 months. The filing states cash disbursements from operations were forecast at approximately $565,000 per month for the next 12 months, before offsetting product and royalty revenue. These are management expectations, not a guarantee of funding.
- The independent auditor’s report included a going-concern explanatory paragraph: recurring losses, negative operating cash flows and liquidity conditions raised substantial doubt about the company’s ability to continue as a going concern.
- Management reported a material weakness in internal control over financial reporting, related to limited accounting staff, lack of segregation of duties and insufficient monitoring and review of the CFO’s financial reporting work. Management concluded both internal controls over financial reporting and disclosure controls were ineffective at year-end.
- MuGard had Chinese regulatory and marketing approval; partners anticipated Chinese sales beginning in the second quarter of 2013. Interim results from an ongoing MuGard study were described as favorable on certain measures, but enrollment continued and the filing does not establish final trial outcomes.
- ProLindac’s further development depended on the China licensee and financing or partners; the company disclosed no assurance that trials, regulatory approval or commercialization would succeed. Revenue generation, partner performance, reimbursement, competition, manufacturing and capital availability were significant risks.
- A purported class action concerning Genaera and its liquidating trust named the company and certain executives. The company moved to dismiss the claims and said it intended to defend the case; the filing does not state a clear estimate of potential exposure.
- Preferred-stock dividends, anti-dilution provisions, derivative accounting and warrants create potential dilution and material noncash earnings volatility. Series A and Series B preferred shares were convertible into approximately 58.3 million and 20 million common shares, respectively, based on filing disclosures.
Important facts for investors to verify
- Confirm the issuer: the supplied filing is for Access Pharmaceuticals, Inc., whereas the request identifies Abeona Therapeutics Inc.
- Reconcile the filing’s working-capital-deficit wording: it reports $4.948 million at year-end and says the deficit increased by $3.929 million from $8.877 million in 2011, although those values indicate a decrease.
- Confirm the secured-note repayment date; the filing reports November 2, 2012 in its business and cash-flow discussion but November 2, 2013 in the debt note.
- Assess liquidity after year-end, the timing and terms of any additional financing, and whether the forecast runway through the third quarter of 2013 was achieved.
- Review the fully diluted share count and economic impact of Series A and Series B preferred stock, dividends, warrants, anti-dilution terms and registration-related liquidated damages.
- Check subsequent MuGard sales and trial results, the status of a new European partner, Chinese commercialization, and ProLindac development plans.
- Track remediation of the material weakness and the status and potential consequences of the Genaera-related litigation.